Futura’s Eroxon OTC Erectile Dysfunction Gel Gets UK Launch
Executive Summary
UK R&D firm Futura has launched in its home market its drug-free erectile dysfunction gel under the Eroxon brand, marketed by France's Cooper Consumer Health.
You may also be interested in...
Haleon Enters US OTC Erectile Dysfunction Race With Futura Deal
Haleon steps into the US OTC erectile dysfunction market with a commercialization deal for Futura's drug-free MED3000 gel, recently approved by the FDA as a de novo medical device.
‘A Phenomenon’ – Futura’s Eroxon ED Gel Gets Off To Flying Start In The UK
According to Futura's UK distributor, the recent launch of its Eroxon drug-free erectile dysfunction gel has been an outstanding success. Ceuta's Jon Connolly described the strategy behind the launch at a recent investor event.
ED Indication Reaches US OTC Market With FDA Approval Of UK Firm Futura’s Eroxon Gel
Approved through De Novo regulatory pathway used to classify novel medical devices for which there is no legally marketed predicate product, Eroxon, packaged in single-use tubes, gives Futura first entry to US market for OTC therapeutic products approved with ED indication.